We have located links that may give you full text access.
Clinical Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Outcomes of 27 Gauge Microincision Vitrectomy Surgery for Posterior Segment Disease.
American Journal of Ophthalmology 2016 January
PURPOSE: To report the initial experience, clinical outcomes, and safety profile of 27 gauge pars plana vitrectomy (PPV) in eyes with posterior segment disease.
DESIGN: Multicenter, retrospective, interventional case series.
METHODS: setting: Private practice and tertiary care settings.
STUDY POPULATION: Eyes undergoing 27 gauge PPV for a vitreoretinal surgery indication.
INTERVENTION: Three-port, transconjunctival 27 gauge PPV.
MAIN OUTCOME MEASURES: Change in visual acuity and occurrence of intraoperative and postoperative complications with minimum follow-up of 90 days.
RESULTS: Ninety-five eyes met the inclusion criteria. Surgical indications included epiretinal membrane (n = 26), diabetic tractional retinal detachment (n = 14), full-thickness macular hole (n = 11), rhegmatogenous retinal detachment with (n = 7) or without (n = 9) proliferative vitreoretinopathy (PVR), vitreous hemorrhage (n = 10), vitreous opacities (n = 8), endophthalmitis (n = 4), sub-silicone oil retinal detachment (n = 3), retained lens material (n = 1), submacular hemorrhage (n = 1), and aqueous misdirection (n = 1). Mean logMAR visual acuity improved from 1.08 ± 0.71 (20/240 Snellen equivalent) preoperatively to 0.53 ± 0.65 (20/67 Snellen equivalent) postoperatively (P < .001). Mean follow-up was 144 days (median 127 days, range 90-254 days). There were no intraoperative complications and no case required conversion to 20, 23, or 25 gauge instrumentation. A total of 3 sclerotomy sites (1.1%) were sutured at the conclusion of surgery. Postoperative complications included transient ocular hypertension in 8 eyes (8.4%), transient hypotony in 5 eyes (5.3%), and vitreous hemorrhage in 5 eyes (5.3%). No cases of postoperative endophthalmitis, sclerotomy-related retinal tears, or choroidal detachments were encountered in the follow-up period.
CONCLUSION: The 27 gauge PPV was well tolerated with low rates of intraoperative and postoperative complications across varied surgical indications.
DESIGN: Multicenter, retrospective, interventional case series.
METHODS: setting: Private practice and tertiary care settings.
STUDY POPULATION: Eyes undergoing 27 gauge PPV for a vitreoretinal surgery indication.
INTERVENTION: Three-port, transconjunctival 27 gauge PPV.
MAIN OUTCOME MEASURES: Change in visual acuity and occurrence of intraoperative and postoperative complications with minimum follow-up of 90 days.
RESULTS: Ninety-five eyes met the inclusion criteria. Surgical indications included epiretinal membrane (n = 26), diabetic tractional retinal detachment (n = 14), full-thickness macular hole (n = 11), rhegmatogenous retinal detachment with (n = 7) or without (n = 9) proliferative vitreoretinopathy (PVR), vitreous hemorrhage (n = 10), vitreous opacities (n = 8), endophthalmitis (n = 4), sub-silicone oil retinal detachment (n = 3), retained lens material (n = 1), submacular hemorrhage (n = 1), and aqueous misdirection (n = 1). Mean logMAR visual acuity improved from 1.08 ± 0.71 (20/240 Snellen equivalent) preoperatively to 0.53 ± 0.65 (20/67 Snellen equivalent) postoperatively (P < .001). Mean follow-up was 144 days (median 127 days, range 90-254 days). There were no intraoperative complications and no case required conversion to 20, 23, or 25 gauge instrumentation. A total of 3 sclerotomy sites (1.1%) were sutured at the conclusion of surgery. Postoperative complications included transient ocular hypertension in 8 eyes (8.4%), transient hypotony in 5 eyes (5.3%), and vitreous hemorrhage in 5 eyes (5.3%). No cases of postoperative endophthalmitis, sclerotomy-related retinal tears, or choroidal detachments were encountered in the follow-up period.
CONCLUSION: The 27 gauge PPV was well tolerated with low rates of intraoperative and postoperative complications across varied surgical indications.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app